| Literature DB >> 35307005 |
Theodosia Salika1, Rebecca M Turner2, David Fisher2, Jayne F Tierney2, Ian R White2.
Abstract
BACKGROUND: Systematic reviews and meta-analysis of time-to-event outcomes are frequently published within the Cochrane Database of Systematic Reviews (CDSR). However, these outcomes are handled differently across meta-analyses. They can be analysed on the hazard ratio (HR) scale or can be dichotomized and analysed as binary outcomes using effect measures such as odds ratios (OR) or risk ratios (RR). We investigated the impact of reanalysing meta-analyses from the CDSR that used these different effect measures.Entities:
Keywords: Clinical trials; Cochrane database of systematic reviews; Meta-analysis; Methodology; Survival data; Time-to-event
Mesh:
Year: 2022 PMID: 35307005 PMCID: PMC8934481 DOI: 10.1186/s12874-022-01541-9
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Fig. 1Analysis sample of “binary” and “OEV” datasets from the CDSR (2008, issue 1)
Descriptive statistics for “binary” and “OEV” data from the CDSR
| Total Number of MA | 715 | |
| Number of studies per MA: Median (IQR) | 5 (3, 8) | |
| Number of events per MA: Median (IQR) | 13 (4, 40) | |
| Median Study Size (IQR) | 124 (60, 312) | |
| Total Number of MA | 69 | 31 |
| Number of studies per MA: Median (IQR) | 10 (6, 14) | 10 (7, 14) |
| Number of events per MA: Median (IQR) | 108 (58, 254) | 104 (70, 192) |
| Median Study Size (IQR) | 182 (93, 369) | 185 (90, 317) |
Distribution of medical specialties for the “binary” and “OEV” data meta-analyses in the CDSR
| Cancer | 95 (13%) | 49 (17, 120) | ||
| Cardiovascular | 168 (23%) | 14 (4, 43) | ||
| Central nervous system/musculoskeletal | 44 (6%) | 12 (5, 33) | ||
| Digestive/endocrine, nutritional and metabolic | 71 (10%) | 7 (3, 18) | ||
| Gynaecology, pregnancy and birth | 87 (12%) | 7 (2, 20) | ||
| Infectious diseases | 46 (6%) | 18 (8, 47) | ||
| Mental health and behavioural conditions | 21 (3%) | 2 (1, 5) | ||
| Pathological conditions, symptoms and signs | 5 (1%) | 9 (2, 15) | ||
| Respiratory diseases | 87 (12%) | 11 (5, 36) | ||
| Urogenital | 30 (4%) | 4 (2, 12) | ||
| Othera | 61 (9%) | 9 (3, 27) | ||
| Cancer | 60 (87%) | 104 (45, 221) | 31 (100%) | 116 (56, 243) |
| Digestive/endocrine, nutritional and metabolic | 1 (1%) | 52 (35, 64) | - | - |
| Infectious diseases | 8 (12%) | 482 (160, 1109) | - | - |
aOther: Blood and immune system, General heath, Injuries, Mouth and dental, and Cystic fibrosis
bACM All-cause mortality;
cOS Overall Survival;
dPDFS: Progression/Disease free survival
Number (%) of (non-)significant meta-analyses under different scales for two-stage models (“binary” and “OEV” data)
| Significant | Non-significant | Significant | Non-Significant | |||
| All-cause mortality | Significant | 106 (15%) | 2 (0.1%) | |||
| Non-significant | 4 (0.6%) | 603 (84%) | ||||
| Significant | Non-significant | Significant | Non-Significant | |||
| Overall Survival | Significant | 20 (29%) | 1 (0.2%) | 18 (26%) | 10 (14%) | |
| Non-significant | 1 (0.2%) | 47 (68%) | 3 (4%) | 38 (55%) | ||
| Progression / Disease free Survival | Significant | 9 (29%) | 0 (0%) | 8 (26%) | 6 (19%) | |
| Non-significant | 1 (3%) | 21 (68%) | 1 (3%) | 16 (52%) | ||
| Overall Survival | Significant | 18 (26%) | 10 (14%) | |||
| Non-significant | 3 (4%) | 38 (55%) | ||||
| Progression / Disease free Survival | Significant | 9 (29%) | 5 (16%) | |||
| Non-significant | 1 (3%) | 16 (52%) | ||||
Fig. 2Bland–Altman plots comparing standardised pooled effect and estimates for two-stage models (“binary” data)
Fig. 3Forest plot (MA 327) indicating discrepancies in the presence of high event probability
Fig. 4Forest plot (MA 330) indicating discrepancies arising from differences in between-study heterogeneity
Fig. 5Bland–Altman Plot comparing standardised OR vs. HR estimates for two-stage models in “OEV” data
Fig. 6Bland–Altman Plot comparing estimates (OR vs. HR) for two-stage models in “OEV” data
Fig. 7Forest plot (MA 45) indicating discrepancies in the presence of high event probability
Fig. 8Forest plot (MA 90) indicating discrepancies arising from differences in between-study heterogeneity